PGS ASA: Implementation of Employee 2021 Long Term Incentive Plan
May 14, 2021: Oslo, Norway, PGS (or the Company ) announces that the 2021 Long Term Incentive Plan (“LTI Plan”), as approved by the Annual General Meeting on April 21, 2021, has now been implemented by allocating 5 993 000 Performance Restricted Stock Units ( PRSUs ).
The awards are based on amongst other considerations the position in the Company and a review on the individual participant s performance prior to award. Any PRSU awarded will, subject to the participant s continued employment with PGS and the Company reaching certain financial goals, be settled three years after award. The complete terms and conditions of the LTI Plan are described in the calling notice for the 2021 Annual General Meeting.
flatexDEGIRO AG: Successful merger of DeGiro B.V. into flatexDEGIRO Bank AG
DGAP-News: flatexDEGIRO AG / Key word(s): Miscellaneous
11.05.2021 / 12:30
Corporate News / Frankfurt/Main, 11 May 2021
Successful merger of DeGiro B.V. into flatexDEGIRO Bank AG
- Legal merger simplifies Group structures, reduces complexity and costs
- Strengthened branch management team to further accelerate international growth
- DEGIRO customers will benefit from new product and service offers launched in H2 2021
- Significant upside to annual EUR 30m+ synergy guidance expected in the medium term
- Vision 2025 under review due to the Group s excellent operating performance
Frankfurt/Main - flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe s largest retail online broker has successfully finalized the legal merger of its subsidiaries DeGiro B.V. and flatexDEGIRO Bank AG and further strengthens the DEGIRO leadership team. In addition to his current role as Group CFO, M
About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence s proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;